Immunome Inc (IMNM)

$14.01 +0.19 (1.37%)
Market Cap 1.20B
Revenue (ttm) 9.04M
Net Income (ttm) -292.96M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,240.71%
Debt to Equity Ratio 0.00
Volume 1,834,800
Avg Vol 1,258,858
Day's Range N/A - N/A
Shares Out 87.05M
Stochastic %K 84%
Beta 1.94
Analysts Strong Sell
Price Target $24.09

Company Profile

Immunome, Inc., a clinical-stage biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. Its preclinical assets include IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug...

Industry: Biotechnology
Sector: Healthcare
Phone: 425 939 7410
Address:
18702 North Creek Parkway, Suite 100, Bothell, United States
HunterT
HunterT Oct. 8 at 4:42 PM
$IMNM something’s cooking here👨🏻‍🍳
0 · Reply
JasonBudd06
JasonBudd06 Oct. 8 at 2:17 PM
$DEFT still consider you the best of people. If you're interested, 3 more on nobody's radar yet that I really like are: $GSRT (tomorrow will be $NKLR), $NUKK, and $IMNM.
4 · Reply
satsandstocks
satsandstocks Oct. 6 at 11:41 PM
$IMNM may god blees this stock
0 · Reply
trendtrader6
trendtrader6 Oct. 6 at 11:08 PM
$IMNM weekly chart. moving well. over 16 should get to 20-22.
0 · Reply
Tommyj1014
Tommyj1014 Oct. 6 at 8:54 PM
$IMNM glad i held into this one
0 · Reply
oldpoorboy
oldpoorboy Oct. 6 at 8:34 PM
$IMNM Next leg up only after 15C burns to zero
0 · Reply
oldpoorboy
oldpoorboy Oct. 6 at 6:19 PM
$IMNM Longs ! do not sell for pennies.
0 · Reply
oldpoorboy
oldpoorboy Oct. 6 at 4:21 PM
$IMNM Yaaaaay not selling until 21
1 · Reply
darkzone_ai
darkzone_ai Oct. 5 at 7:41 AM
$IMNM Medical technology innovation. Testing resistance at descending trendline. Volume decline suggests lack of conviction.
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 4 at 11:45 AM
$RADX Do your due diligence https://scr.zacks.com/news/news-details/2025/RADX-RAD101-Imaging-Recurring-Brain-Metastases-article/default.aspx $PYXS $IMNM $ADCT $INMB
0 · Reply
Latest News on IMNM
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 2, 2025, 5:05 PM EDT - 6 days ago

Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Infinimmune Announces Research Collaboration with Immunome

Sep 18, 2025, 8:00 AM EDT - 21 days ago

Infinimmune Announces Research Collaboration with Immunome

Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 8:00 AM EDT - 5 weeks ago

Immunome to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Immunome: SpringWorks Buyout Informs The Potential Upside Here

Aug 11, 2025, 10:31 PM EDT - 2 months ago

Immunome: SpringWorks Buyout Informs The Potential Upside Here

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

Aug 6, 2025, 4:05 PM EDT - 2 months ago

Immunome Reports Second Quarter 2025 Financial Results and Provides Business Update

Immunome to Present at Upcoming Investor Conferences

May 22, 2025, 8:00 AM EDT - 5 months ago

Immunome to Present at Upcoming Investor Conferences

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

May 12, 2025, 4:05 PM EDT - 5 months ago

Immunome Reports First Quarter 2025 Financial Results and Provides Business Update

Immunome: Transformed Pipeline Offers Multiple Catalysts

Apr 17, 2025, 6:06 AM EDT - 6 months ago

Immunome: Transformed Pipeline Offers Multiple Catalysts

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Apr 4, 2025, 8:00 AM EDT - 6 months ago

Immunome to Present at the 24th Annual Needham Virtual Healthcare Conference

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Mar 19, 2025, 4:05 PM EDT - 7 months ago

Immunome Reports Full Year 2024 Financial Results and Provides Business Update

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Mar 10, 2025, 7:41 AM EDT - 7 months ago

Immunome Doses First Patient in Phase 1 Trial of IM-1021, a ROR1-Targeted ADC

Immunome to Present at Upcoming March Conferences

Feb 25, 2025, 8:00 AM EST - 8 months ago

Immunome to Present at Upcoming March Conferences

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Jan 31, 2025, 4:01 PM EST - 8 months ago

Immunome Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Immunome Can Take The Fight To Competitors With Varegacestat

Jan 30, 2025, 10:27 AM EST - 8 months ago

Immunome Can Take The Fight To Competitors With Varegacestat

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Jan 29, 2025, 11:11 PM EST - 9 months ago

Immunome Announces Pricing of Upsized Public Offering of Common Stock

Immunome Announces Proposed Public Offering of Common Stock

Jan 29, 2025, 4:27 PM EST - 9 months ago

Immunome Announces Proposed Public Offering of Common Stock

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 13, 2025, 8:00 AM EST - 9 months ago

Immunome Provides Pipeline Update in Advance of Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Nov 27, 2024, 8:00 AM EST - 11 months ago

Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Nov 13, 2024, 4:05 PM EST - 11 months ago

Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Nov 5, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at Guggenheim's Inaugural Healthcare Innovation Conference

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Oct 29, 2024, 8:00 AM EDT - 1 year ago

Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Oct 18, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Oct 8, 2024, 8:05 AM EDT - 1 year ago

Immunome Appoints Roee Shahar as Executive Vice President, Commercial

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Sep 13, 2024, 7:00 AM EDT - 1 year ago

Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Aug 29, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 12, 2024, 4:01 PM EDT - 1 year ago

Immunome Reports Second Quarter 2024 Financial Results and Provides Business Update

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Jul 25, 2024, 8:00 AM EDT - 1 year ago

Immunome Provides Update on Recent Business Development Activity Expected to Expand ADC Capabilities

Immunome: AL102 And Other Established Protein Targets Could Drive Value

Jun 27, 2024, 2:14 PM EDT - 1 year ago

Immunome: AL102 And Other Established Protein Targets Could Drive Value

Immunome Appoints Phil Tsai as Chief Technical Officer

Jun 27, 2024, 8:00 AM EDT - 1 year ago

Immunome Appoints Phil Tsai as Chief Technical Officer

Immunome Announces Completion of Purchase of Assets from Atreca

May 20, 2024, 8:00 AM EDT - 1 year ago

Immunome Announces Completion of Purchase of Assets from Atreca

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

May 17, 2024, 8:00 AM EDT - 1 year ago

Immunome Announces Promotion of Max Rosett to Chief Financial Officer

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

May 14, 2024, 8:00 AM EDT - 1 year ago

Immunome Reports First Quarter 2024 Financial Results and Provides Business Update

Immunome to Present at 2024 Bank of America Healthcare Conference

May 8, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present at 2024 Bank of America Healthcare Conference

Immunome Appoints Kinney Horn as Chief Business Officer

May 2, 2024, 8:00 AM EDT - 1 year ago

Immunome Appoints Kinney Horn as Chief Business Officer

Immunome Appoints Sandra M. Swain to Board of Directors

Apr 25, 2024, 8:26 AM EDT - 1 year ago

Immunome Appoints Sandra M. Swain to Board of Directors

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Apr 5, 2024, 8:00 AM EDT - 1 year ago

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting

Immunome: An Oncology Powerhouse In The Making

Apr 2, 2024, 2:07 PM EDT - 1 year ago

Immunome: An Oncology Powerhouse In The Making

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Mar 28, 2024, 4:02 PM EDT - 1 year ago

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Mar 26, 2024, 8:00 AM EDT - 1 year ago

Immunome Completes Acquisition of AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala

Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

Mar 18, 2024, 5:44 AM EDT - 1 year ago

Arrayjet's ArrayPlex Platform Selected by Immunome for Use in Its Discovery of Targeted Cancer Therapies

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Mar 7, 2024, 8:00 AM EST - 1 year ago

Immunome to Participate in the Leerink Partners Global Biopharma Conference

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

Mar 1, 2024, 8:00 AM EST - 1 year ago

Immunome to Participate in the TD Cowen 44th Annual Healthcare Conference

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Feb 20, 2024, 8:15 AM EST - 1 year ago

Immunome Recognizes Ayala Pharmaceuticals' Announced Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Feb 16, 2024, 4:05 PM EST - 1 year ago

Immunome Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

Immunome Announces Pricing of Public Offering of Common Stock

Feb 13, 2024, 10:38 PM EST - 1 year ago

Immunome Announces Pricing of Public Offering of Common Stock

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

Feb 6, 2024, 8:00 AM EST - 1 year ago

Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals

Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 5, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform

Jan 8, 2024, 7:00 AM EST - 1 year ago

Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology Platform

ZNTL

Immunome Appoints Phil Roberts as Chief Technical Officer

Jan 4, 2024, 8:00 AM EST - 1 year ago

Immunome Appoints Phil Roberts as Chief Technical Officer

Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 3, 2024, 8:00 AM EST - 1 year ago

Immunome to Present at the 42nd Annual J.P. Morgan Healthcare Conference

HunterT
HunterT Oct. 8 at 4:42 PM
$IMNM something’s cooking here👨🏻‍🍳
0 · Reply
JasonBudd06
JasonBudd06 Oct. 8 at 2:17 PM
$DEFT still consider you the best of people. If you're interested, 3 more on nobody's radar yet that I really like are: $GSRT (tomorrow will be $NKLR), $NUKK, and $IMNM.
4 · Reply
satsandstocks
satsandstocks Oct. 6 at 11:41 PM
$IMNM may god blees this stock
0 · Reply
trendtrader6
trendtrader6 Oct. 6 at 11:08 PM
$IMNM weekly chart. moving well. over 16 should get to 20-22.
0 · Reply
Tommyj1014
Tommyj1014 Oct. 6 at 8:54 PM
$IMNM glad i held into this one
0 · Reply
oldpoorboy
oldpoorboy Oct. 6 at 8:34 PM
$IMNM Next leg up only after 15C burns to zero
0 · Reply
oldpoorboy
oldpoorboy Oct. 6 at 6:19 PM
$IMNM Longs ! do not sell for pennies.
0 · Reply
oldpoorboy
oldpoorboy Oct. 6 at 4:21 PM
$IMNM Yaaaaay not selling until 21
1 · Reply
darkzone_ai
darkzone_ai Oct. 5 at 7:41 AM
$IMNM Medical technology innovation. Testing resistance at descending trendline. Volume decline suggests lack of conviction.
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 4 at 11:45 AM
$RADX Do your due diligence https://scr.zacks.com/news/news-details/2025/RADX-RAD101-Imaging-Recurring-Brain-Metastases-article/default.aspx $PYXS $IMNM $ADCT $INMB
0 · Reply
RadioIsotope25
RadioIsotope25 Oct. 1 at 2:49 PM
$RADX $PYXS $IMNM $SMMT Trading at 50% discount to last strategic investment from Lantheus
1 · Reply
StockScanners
StockScanners Sep. 30 at 1:22 AM
$IMNM reached 11.86
0 · Reply
WycklyTrader
WycklyTrader Sep. 29 at 11:07 PM
$IMNM potential breakout with phase 3 data due December. QNCX potential trend reversal with phase 3 data due 1Q2026. Potential short-cover bounce plays: $MLTX, $KALA, $LRMR
0 · Reply
Johnuser541
Johnuser541 Sep. 29 at 1:17 PM
$IMNM lots of other biotechs releasing bad data today
0 · Reply
RadioIsotope25
RadioIsotope25 Sep. 27 at 8:17 PM
$RADX Radiopharm Theranostics (Nasdaq: RADX) ———-RAD202—— October Data — $7.5 to $15 billion yearly market opportunity per ChatGPT llm. 100,000 to 200,000 patients globally and $75,000 price tag. Nsclc, head & neck and melanoma https://www.oncidiumfoundation.org/wp-content/uploads/2025/04/177Lu-anti-PD-L1-sdAb.pdf Lantheus bought more at $12 in first quarter. Leader in Radiopharma field. Insiders invested heavily past 24 mos $PYXS $IMNM $MNPR
3 · Reply
JasonBudd06
JasonBudd06 Sep. 27 at 5:39 PM
$DEFT throwing my beaten down deft friends a bone with $IMNM . Good luck
3 · Reply
JasonBudd06
JasonBudd06 Sep. 27 at 5:35 PM
$IMNM Just a matter of time
1 · Reply
Doozio
Doozio Sep. 27 at 4:04 PM
$IMNM Thursday 🐑🎁s and FRYday closes because all them bums been SPOT. How can yo BE SKWD of a correction if it’s chop chop huckleberries n the 🧠 starts making that $DASH again. 🐒🍌🧠⏰♾️
0 · Reply
StockScanners
StockScanners Sep. 27 at 4:28 AM
$IMNM keep watch if this holds above 11
0 · Reply
Johnuser541
Johnuser541 Sep. 26 at 8:30 PM
$IMNM exciting end to the week
0 · Reply
RunnerSignals
RunnerSignals Sep. 26 at 8:29 PM
Market Warriors Bounce Back Big Today $DKI $SKBL $IMNM $CLPT $RITR turned the tables and closed strong
0 · Reply
Jeff9905
Jeff9905 Sep. 26 at 8:04 PM
$IMNM up on 6x volume. Data must be good.
0 · Reply